An interventional study of TENS in Diabetes type2 and Hyposalivation, sponsored by Cairo University. Status unknown at 1 site in Egypt. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2018-02-19.
Sponsored by Cairo University · Not applicable, Interventional, and Treatment
Among 19 studies in Xerostomia with a site in Egypt — 3 open to participants now, 5 under way, 1 of them phase 3. Xerostomia · Egypt.
Among the 19 studies in Xerostomia with a site in Egypt, this one has the largest planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2017, is one of 12 with no phase, and was the 2nd registered.
286 studies on the registry are indexed under Xerostomia; 51 are open to participants now.
Browse Xerostomia studies →3 of the 19 studies in Xerostomia with a site in Egypt are open now. Recruiting first, the newest first:
Alexandria University · Sites in Egypt
Ages 18+
Ain Shams University · Sites in Egypt
Ages 20–70
Ain Shams University · Sites in Egypt
Ages 20–70
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 26 Xerostomia studies recruiting now, 15 (58%) set no upper age limit and 7 (27%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.
This study: 50 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 1 started in 2017.
This study's planned enrollment of 100 is above the median of 44 across 235 interventional studies indexed under Xerostomia.
Median enrollment 44 across the 16 interventional studies, 260 across the 3 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 19 has an industry lead sponsor. The 8 most frequent:
Cairo University is the lead sponsor of 4,941 studies on the registry; 1,457 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Cairo University has 2 studies filed under Xerostomia — fewer than ten, so there is no comparison to draw.
1 of the studies in Xerostomia with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07476209Alexandria UniversitySialendoscopy Versus Photobiomodulation in Prevention of Radiation Induced Xerostomia | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Xerostomia with a site in Egypt, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluates response of abnormal low salivary flow rate to transcutaneous electrical nerve stimulation (TENS) in diabetic type 2 patients. Response of saliva monitored for all participants receiving only one session of 5-minute extraoral TENS on bilateral parotid glands.
Diabetes mellitus is the most significant disorder associated with varied oral manifestation ranging from xerostomia (subjective sensation od dry mouth) to serious bacterial and fungal infections due to alterations in flow rate of saliva.
Systemic agents increase rate of stimulated salivary flow but often have unfavourable side effects such as profuse sweating, rhinitis, dyspepsia.
Use of TENS in stimulation of saliva has been studied in the past which showed moderate promising results. However, it never became a part of the mainstream therapy of hyposalivation.
It has been postulated that transcutaneous electric nerve stimulation (TENS) could directly stimulate the auriculotemporal nerve, which supplies the parotid gland, whereas it remains unclear whether there is also an indirect action (via afferent pathways) onto the salivary reflex arch.
Starting a prevention program as early as possible considering the most practical, cost effective and efficient treatments with the best risk-benefit ratio will help to diminish dry mouth symptoms and sequelae (intraoral and extraoral complications).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
one group receiving TENS: - The electrode of TENS unit will be placed vertically, externally on skin overlying the parotid gland, in the preauricular area bilaterally, 1 cm in front of the tragus area.
Device: TENS
* Duration of stimulation: 5 minutes. * Frequency: will be fixed at 50 Hertz. * Pulse duration: 250 µs. * Intensity: optimal intensity of TENS (amplitude will be gradually increased to the maximum intensity that the subject will be comfortable and tolerate it). * Sessions: only one session
salivary volume
It is estimated as follow: * The patients advised to have nothing to eat, drink, chew gum, intake coffee and oral hygiene before the test. * whole resting salivary volume (ml) planned to be performed using low forced spitting technique in graduated test tube before TENS application. * stimulated salivary volume (ml) collected after TENS application is compared to whole resting salivary volume to assess improvement. .
Time frame: After only one session of five-minutes TENS
salivary flow rate
It is estimated as follow: * By dividing whole resting salivary volume on five minute collection period , thus whole resting salivary flow rate (ml/minute) is obtained. * Dividing stimulated salivary volume - collected after TENS application - on five minute collection period, thus stimulated salivary flow rate (ml/minute) is obtained. * Assessing improvement is done by comparing stimulated with whole resting salivary flow rate.
Time frame: After only one session of five-minutes TENS
Eight-item visual analogue scale xerostomia questionnaire
* Visual analogue scale is a horizontal line,100 millimeters (mm) in length and anchored by word descriptors at each end. * Items are "Rate the difficulty you experience in swallowing due to dryness", "Rate the difficulty you experience in speaking due to dryness","Rate how much saliva is in your mouth","Rate the dryness of your mouth", "Rate the dryness of your throat", "Rate the dryness of your lips", "Rate the dryness of your tongue" ," Rate the level of your thirst" respectively. * Before and after treatment, the researcher ask each item to the patient.Then, the patient ts asked to mark his response (perception of his current state) for the item by placing a vertical line on the scale of each item. * The researcher determine scale score response of each item by measuring distance in mm. * Decreased post-treatment of visual analogue scale score for each item considered improvement.
Time frame: After only one session of five-minutes TENS
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2017 (actual). Primary completion is estimated for May 2018, 16 months after the start.
Of 85 non-industry interventional studies with no phase under Xerostomia, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 33. This study's planned 16 months is close to that.
Counting every sponsor, half of 101 studies reached it within 13 months; a quarter within 4 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.